Larry E. Fields

3.3k total citations · 2 hit papers
31 papers, 2.7k citations indexed

About

Larry E. Fields is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Immunology. According to data from OpenAlex, Larry E. Fields has authored 31 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Cardiology and Cardiovascular Medicine, 7 papers in Internal Medicine and 5 papers in Immunology. Recurrent topics in Larry E. Fields's work include Atrial Fibrillation Management and Outcomes (12 papers), Venous Thromboembolism Diagnosis and Management (7 papers) and Antiplatelet Therapy and Cardiovascular Diseases (5 papers). Larry E. Fields is often cited by papers focused on Atrial Fibrillation Management and Outcomes (12 papers), Venous Thromboembolism Diagnosis and Management (7 papers) and Antiplatelet Therapy and Cardiovascular Diseases (5 papers). Larry E. Fields collaborates with scholars based in United States, Belgium and Cyprus. Larry E. Fields's co-authors include Edward J. Roccella, Paul D. Sorlie, Thomas Thom, Michael Wolz, Jeffrey A. Cutler, Vicki L. Burt, Dennis Y. Loh, Izumi Negishi, Keiko Nakayama and Philip J. Lucas and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Larry E. Fields

30 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trends in Hypertension Prevalence, Awareness, Treatment, and Control Rates in United States Adults Between 1988–1994 and 1999–2004

2008 704 citations Jeffrey A. Cutler, Paul D. Sorlie et al. Hypertension profile →
The Burden of Adult Hypertension in the United States 1999 to 2000

2004 698 citations Larry E. Fields, Edward J. Roccella et al. Hypertension profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Larry E. Fields United States	17	1.3k	530	377	320	269	31	2.7k
Lisa R. Yanek United States	30	1.4k 1.0×	173 0.3×	361 1.0×	393 1.2×	232 0.9×	143	3.3k
Antonio Muscari Italy	28	698 0.5×	433 0.8×	474 1.3×	127 0.4×	164 0.6×	88	2.8k
Maria Boddi Italy	31	1.3k 1.0×	159 0.3×	398 1.1×	113 0.4×	179 0.7×	102	2.6k
Susan G. Lakoski United States	32	1.4k 1.0×	222 0.4×	238 0.6×	416 1.3×	108 0.4×	71	3.6k
Jeetesh V. Patel United Kingdom	24	903 0.7×	121 0.2×	301 0.8×	150 0.5×	161 0.6×	52	2.1k
G.D.O. Lowe United Kingdom	26	1.0k 0.7×	389 0.7×	232 0.6×	202 0.6×	495 1.8×	70	3.7k
Gavin J. Blake United States	19	806 0.6×	357 0.7×	325 0.9×	138 0.4×	83 0.3×	33	2.4k
Reecha Sofat United Kingdom	23	835 0.6×	212 0.4×	300 0.8×	127 0.4×	237 0.9×	71	2.3k
Egidio Celentano Italy	26	469 0.3×	113 0.2×	275 0.7×	376 1.2×	69 0.3×	83	2.1k
A. Evans France	35	1.5k 1.2×	293 0.6×	788 2.1×	394 1.2×	90 0.3×	68	4.5k

Countries citing papers authored by Larry E. Fields

Since Specialization

Citations

This map shows the geographic impact of Larry E. Fields's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larry E. Fields with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larry E. Fields more than expected).

Fields of papers citing papers by Larry E. Fields

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Larry E. Fields. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larry E. Fields. The network helps show where Larry E. Fields may publish in the future.

Co-authorship network of co-authors of Larry E. Fields

This figure shows the co-authorship network connecting the top 25 collaborators of Larry E. Fields. A scholar is included among the top collaborators of Larry E. Fields based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Larry E. Fields. Larry E. Fields is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fields, Larry E.. (2016). Limiting rights: the dilemma of judicial review.

Alberts, Mark J., W. Frank Peacock, Larry E. Fields, et al.. (2016). Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. International Journal of Cardiology. 215. 11–13. 47 indexed citations

Nguyen, Elaine, C Michael White, Manesh R. Patel, et al.. (2016). Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials. Current Medical Research and Opinion. 32(7). 1277–1279. 25 indexed citations

Mahan, Charles E., Larry E. Fields, Roger M. Mills, et al.. (2015). All-cause mortality and use of antithrombotics within 90 days of discharge in acutely ill medical patients. Thrombosis and Haemostasis. 114(10). 685–694. 2 indexed citations

Nelson, Winnie W., et al.. (2015). International Normalized Ratio Stability in Warfarin-Experienced Patients with Nonvalvular Atrial Fibrillation. American Journal of Cardiovascular Drugs. 15(3). 205–211. 32 indexed citations

Peacock, W. Frank, Manesh R. Patel, Nicholas Sicignano, et al.. (2015). Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban. Clinical Cardiology. 38(2). 63–68. 127 indexed citations

Moore, Kenneth Todd, et al.. (2014). Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube. Clinical Pharmacology in Drug Development. 3(4). 321–327. 32 indexed citations

Naccarelli, Gerald V., Riccardo Cappato, Stefan H. Hohnloser, et al.. (2014). Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation. Journal of Interventional Cardiac Electrophysiology. 41(2). 107–116. 13 indexed citations

Olson, William H., Yan Ma, Patrick Lefèbvre, et al.. (2014). Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel. Journal of Clinical Pharmacy and Therapeutics. 39(6). 663–672. 4 indexed citations

10.

Nelson, Winnie W., et al.. (2013). Impact of Co-morbidities and Patient Characteristics on International Normalized Ratio Control Over Time in Patients With Nonvalvular Atrial Fibrillation. The American Journal of Cardiology. 112(4). 509–512. 48 indexed citations

11.

Mahan, Charles E., Maxine D. Fisher, Roger M. Mills, et al.. (2013). Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population. Thrombosis Research. 132(5). 520–526. 44 indexed citations

12.

Chen, Shih‐Yin, Ning Wu, Michael P. Gulseth, et al.. (2013). One-Year Adherence to Warfarin Treatment for Venous Thromboembolism in High-Risk Patients and Its Association with Long-term Risk of Recurrent Events. Journal of Managed Care Pharmacy. 19(4). 291–301. 50 indexed citations

13.

Choi, Jiyoon, C.V. Damaraju, Roger M. Mills, et al.. (2012). IMPACT OF COMORBIDITIES ON TIME IN THERAPEUTIC RANGE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION. Journal of the American College of Cardiology. 59(13). E1855–E1855. 3 indexed citations

14.

Cutler, Jeffrey A., Paul D. Sorlie, Michael Wolz, et al.. (2008). Trends in Hypertension Prevalence, Awareness, Treatment, and Control Rates in United States Adults Between 1988–1994 and 1999–2004. Hypertension. 52(5). 818–827. 704 indexed citations breakdown →

15.

Randolph, David A., James Verbsky, Liping Yang, et al.. (1996). PCR-based gene targeting of the inducible nitric oxide synthase (NOS2) locus in murine ES cells, a new and more cost-effective approach. Transgenic Research. 5(6). 413–420. 5 indexed citations

16.

Verbsky, James, Erika A Bach, Yifu Fang, et al.. (1996). Expression of Janus Kinase 3 in Human Endothelial and Other Non-lymphoid and Non-myeloid Cells. Journal of Biological Chemistry. 271(24). 13976–13980. 64 indexed citations

17.

Azuma, Takachika, Noboru Motoyama, Larry E. Fields, & Dennis Y. Loh. (1993). Mutations of the chloramphenicol acetyl transferase transgene driven by the immunoglobulin promoter and intron enhancer. International Immunology. 5(2). 121–130. 66 indexed citations

18.

Fields, Larry E. & Dennis Y. Loh. (1992). Organ injury associated with extrathymic induction of immune tolerance in doubly transgenic mice.. Proceedings of the National Academy of Sciences. 89(13). 5730–5734. 33 indexed citations

19.

Sobel, Burton E., Jeffrey E. Saffitz, Larry E. Fields, et al.. (1987). Intramuscular administration of human tissue-type plasminogen activator in rabbits and dogs and its implications for coronary thrombolysis.. Circulation. 75(6). 1261–1272. 9 indexed citations

20.

Fields, Larry E., Alan Daugherty, & Steven R. Bergmann. (1986). Effect of fatty acid on performance and lipid content of hearts from diabetic rabbits. American Journal of Physiology-Heart and Circulatory Physiology. 250(6). H1079–H1085. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact